New study points to a strategy for inhibiting hyper-progression of melanoma

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Related Keywords

Michelle Ferreira ,Nicholasc Devito ,Nagendra Yarla ,Brent Hanks ,Linda Cao ,Aprilks Salama ,Balamayooran Theivanthiran ,Alisha Holtzhausen ,Tarek Haykal ,Emily Henderson ,Michaelp Plebanek ,April Salama ,Y Van Nguyen ,Duke Cancer Institute ,Lab Diagnostics Automation ,Lab Diagnostics Automation Industry ,Cancer Institute ,Science Translational ,Duke University School ,Automation Industry Focus ,Rami Al Rohil ,Biomarker ,Melanoma ,Dancer ,Drugs ,Immune System ,Immunotherapy ,Inflammasome ,Medicine ,Melanoma Cells ,Neck ,Humor ,